Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment
With Northway Biotech's expertise in biologics manufacturing, Mallia aims to enter the multi-billion-dollar alopecia market by delivering a safe and effective topical sCD83 treatment designed to stimulate hair follicle formation and promote sustained hair growth.
ERLANGEN, GERMANY AND VILNIUS, LITHUANIA / ACCESS Newswire / February 4, 2025 / Mallia Therapeutics ("Mallia"), a biopharmaceutical company developing novel treatments for hair loss, and Northway Biotech ("NBT"), a biologics Contract Development and Manufacturing Organization (CDMO), have announced a partnership for the development of the production process and manufacturing of Mallia's soluble CD83 protein (sCD83), a treatment aimed at promoting hair follicle formation and growth.
Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop the production process for the recombinant sCD83 protein for large-scale production, utilizing the Pichia pastoris expression system. This collaboration includes the development of analytical methods, technology scale-up, and the manufacturing of a cGMP Drug Substance.
Dr. Manfred Groeppel, co-founder and Managing Director of Mallia Therapeutics, said: "With this partnership, we are advancing the development of sCD83 to turn our research into a scalable treatment for patients."
"Interestingly, sCD83's mode of action induces both the formation of new hair follicles and thus hair growth, and has the potential to redefine treatment approaches for hormone-induced androgenetic alopecia as well as immune-mediated alopecia areata," emphasizes Prof. Dr. Alexander Steinkasserer, co-founder and Managing Director of Mallia. "By developing a robust production process, we are ensuring the quality required for future clinical as well as commercial applications."
Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway Biotech, expressed, "We are excited to be working with Mallia on developing the manufacturing process of sCD83. Our priority is to ensure the highest manufacturing standards and maintain clear, open communication as we collaborate every step of the way."
"Mallia's team and their innovative solution make this project particularly appealing to us given its huge potential and the large need from people all over the world for treatment. The strong and transparent collaboration we have established allows us to support Mallia with confidence as we move forward together quickly,"added André Markmann, PhD, VP of Business Development at Northway Biotech.
About Mallia Therapeutics GmbH
Mallia Therapeutics GmbH is a biopharmaceutical company focused on developing novel treatments for patients suffering from hair loss. The Company was founded in 2023 in Erlangen, Germany, and is led by an experienced management team and worldwide leading experts in the field of CD83, with more than 60 CD83-related publications and 20 years of experience in the field.
With sCD83, a potential treatment for hair loss in preclinical development, Mallia aims to enter the multi-billion-dollar alopecia market and provide patients with a safe and effective topical treatment.
Connect with us on LinkedIn or find out more here: https://mallia-therapeutics.com/
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced and professional team executes projects at every stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's extensive expertise and vertically integrated service offering enable rapid execution of multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development, and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and operates locations in Vilnius, Lithuania; London, United Kingdom; and Waltham, MA, USA. For more information, please visit www.northwaybiotech.com.
Mallia Therapeutics Contact:
Mallia Therapeutics GmbH
info@mallia-therapeutics.com
International Media Contact:
MC Services AG
Dr. Regina Lutz / Katja Arnold
Tel.: +49 (0)89 210 228 0
E-Mail: mallia-therapeutics@mc-services.eu
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
View the original press release on ACCESS Newswire
Northway Biotech
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
IXOPAY Appoints Yasser Abou-Nasr as SVP of Product to Drive Execution and Scale4.2.2025 00:00:00 CET | Press release
Seasoned Fintech Leader Joins IXOPAY to Advance Product Innovation and Drive Scalable Growth in Payment Orchestration. LEHI, UT / ACCESS Newswire / February 4, 2025 / IXOPAY, a leading enterprise payment orchestration platform, announced the appointment of Yasser Abou-Nasr as SVP of Product. With over 16 years of senior product leadership in payments and fintech, Yasser joins IXOPAY to execute the company's strategic vision and scale its product offerings to meet the growing demand for seamless and secure payment solutions. Yasser brings a proven track record of driving product execution at scale, combined with deep expertise in product management, operational transformation, and the development of B2B SaaS platforms. His leadership will be instrumental in advancing IXOPAY's enterprise payment orchestration platform, enabling businesses worldwide to simplify, secure, and optimize their payment systems through scalable and flexible solutions. "Yasser's ability to execute and scale compl
Arctic Wolf and BlackBerry Announce Closing of Acquisition for Cylance3.2.2025 17:05:00 CET | Press release
WATERLOO, ON and EDEN PRAIRIE, MN / ACCESS Newswire / February 3, 2025 / Arctic Wolf® and BlackBerry Limited (NYSE:BB)(TSX:BB), two global leaders in security software and services, today announced the successful closing of the acquisition of BlackBerry's Cylance® endpoint security assets by Arctic Wolf. The two companies entered into a definitive agreement on December 15, 2024. "We are pleased to have successfully closed this pivotal transaction for BlackBerry and look forward to continuing our relationship with Arctic Wolf as a customer, as a reseller of the portfolio to our large government customers, and as a shareholder of this dynamic, growing company," said John Giamatteo, chief executive officer of BlackBerry. "Today, the launch of Aurora Endpoint Security represents a transformative step in how organizations adopt endpoint protection," said Nick Schneider, president and chief executive officer of Arctic Wolf. "By integrating Cylance's advanced AI-driven capabilities into the A
ToolsGroup Recognized as a Leader in the IDC MarketScape: Worldwide Supply Chain Planning for Spare Parts/MRO Industries 20243.2.2025 10:15:00 CET | Press release
BOSTON, MA / ACCESS Newswire / February 3, 2025 / ToolsGroup, a global leader in supply chain planning and retail optimization software, today announced it has been positioned as a Leader in the IDC MarketScape: Worldwide Supply Chain Planning for Spare Parts/MRO Industries 2024 Vendor Assessment (Doc ID #US51541424, December 2024). IDC evaluated 12 key vendors in the Spare Parts/MRO Supply Chain Planning Marketscape based on each vendor's current capabilities and future strategy. ToolsGroup was ranked #1 in current capabilities for Spare Parts/MRO supply chain planning, and an overall leader in the category. IDC specifically recommended ToolsGroup for manufacturers in all industries, especially those with large SKU offerings and/or complex distribution networks. ToolsGroup provides a uniquely effective approach to inventory optimization and demand planning leveraging probabilistic planning and decision support to manage the product line across SKUs. "We're proud to be recognized by ID
DEXIS Reflects on a Year of Innovation and Unveils Exciting Plans for 20253.2.2025 09:30:00 CET | Press release
QUAKERTOWN, PENNSYLVANIA / ACCESS Newswire / February 3, 2025 / DEXIS, an international leader in dental imaging technologies, celebrates the 2024 launch of its DEXIS digital ecosystem along with other AI-powered imaging solutions. The company also announces that 2025 will bring further innovations, with presentations at two major dental technology conferences. "For DEXIS, 2024 was a year of tremendous innovation, as we continue to provide dental professionals with the most powerful, efficient and time-saving diagnostic tools and technologies," DEXIS President Robert Befidi said. "We are proud of our progress and will bring that momentum with us in 2025 as we unveil exciting, industry-changing initiatives." The company enhanced its portfolio of award-winning imaging solutions in 2024, beginning with the February 2024 launch of the DEXIS digital ecosystem, a suite of tools and software designed to connect and streamline the implant workflow. The platform combines cutting-edge CBCT, intr
Formerra Expands Leadership Team to Support Accelerated Global Growth3.2.2025 09:15:00 CET | Press release
ROMEOVILLE, ILLINOIS / ACCESS Newswire / February 3, 2025 / Formerra, a leader in performance materials distribution, announced today that Kyle Poyta has joined the company as Chief Commercial Officer, a newly established role at Formerra. Kyle most recently led Quaker Houghton's North American commercial organization, with prior roles at DuPont.Kyle Poyta named Chief Commercial Officer at Formerra. Kyle's 26 years of experience in specialty chemicals, industrial minerals, and polymer industries will help him to lead and execute Formerra's commercial strategy as the Company enters an inflection point driven by commercial investment, global expansion, and accelerated growth. "As our global strategy unfolds, we're well positioned for an inflection in growth supported by significant investments in our commercial capabilities over the last two years," says Cathy Dodd, Chief Executive Officer, Formerra. "In recent periods, we completed strategic acquisitions in Europe and Mexico, invested i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom